Bayer studies eye drug delivery in collaboration with Johns Hopkins

Bayer is collaborating with Johns Hopkins University's Wilmer Eye Institute to develop new forms of drug delivery to the back of the eye. Targeted diseases include age-related macular degeneration and diabetic macular edema, which both result in in vision loss. More from FierceBiotech

Suggested Articles

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.